The participant may not enter the trial if ANY of the following apply: 1.SARS-CoV-2 infection confirmed by RT-qPCR detection, 2.Clinical manifestations including fever, dry cough, fatigue, nasal congestion, runny nose, sore throat, myalgia, diarrhea, shortness of breath, dyspnea, etc., 3.Body temperature >37.0 degree C before vaccination, 4.Urine pregnancy test positive, 5.Severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioedema or abdominal pain) or allergic to the known ingredients of the inactivated SARS-CoV-2 vaccine, 6.History or family history of convulsions, epilepsy, encephalopathy or mental illness, 7.Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc. 8.Suffer from severe liver and kidney disease, uncontrollable hypertension (systolic blood pressure>=140 mmHg, diastolic blood pressure>=90 mmHg), diabetic complications, malignant tumors, various acute diseases or acute attacks of chronic diseases, 9.Diagnosed as congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases, 10.Are receiving anti-tuberculosis treatment, 11.Known or suspected diseases include severe respiratory diseases, severe cardiovascular diseases, liver and kidney diseases and malignant tumors, 12.History of coagulation dysfunction (such as coagulation factor deficiency, coagulation disease), 13.Receipt of immunotherapy or inhibitor treatment within 3 months (continuous oral or infusion for more than 14 days), 14.Receipt of any live attenuated vaccine within 1 month before this vaccination, and other vaccines within 14 days before this vaccination, 15.Receipt of other study drugs within 6 months before vaccination, 16.The investigator judged that it is not suitable for other situations in this clinical trial.

The participant may not enter the trial if ANY of the following apply: 1.SARS-CoV-2 infection confirmed by RT-qPCR detection, 2.Clinical manifestations including fever, dry cough, fatigue, nasal congestion, runny nose, sore throat, myalgia, diarrhea, shortness of breath, dyspnea, etc., 3.Body temperature >37.0 degree C before vaccination, 4.Urine pregnancy test positive, 5.Severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioedema or abdominal pain) or allergic to the known ingredients of the inactivated SARS-CoV-2 vaccine, 6.History or family history of convulsions, epilepsy, encephalopathy or mental illness, 7.Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc. 8.Suffer from severe liver and kidney disease, uncontrollable hypertension (systolic blood pressure>=140 mmHg, diastolic blood pressure>=90 mmHg), diabetic complications, malignant tumors, various acute diseases or acute attacks of chronic diseases, 9.Diagnosed as congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases, 10.Are receiving anti-tuberculosis treatment, 11.Known or suspected diseases include severe respiratory diseases, severe cardiovascular diseases, liver and kidney diseases and malignant tumors, 12.History of coagulation dysfunction (such as coagulation factor deficiency, coagulation disease), 13.Receipt of immunotherapy or inhibitor treatment within 3 months (continuous oral or infusion for more than 14 days), 14.Receipt of any live attenuated vaccine within 1 month before this vaccination, and other vaccines within 14 days before this vaccination, 15.Receipt of other study drugs within 6 months before vaccination, 16.The investigator judged that it is not suitable for other situations in this clinical trial.